1195765-45-7,MFCD17215684
Catalog No.:AA000IVZ

1195765-45-7 | Dabrafenib

Pack Size
Purity
Availability
Price(USD)
Quantity
  
5mg
≥98%
in stock  
$52.00   $36.00
- +
10mg
≥98%
in stock  
$99.00   $69.00
- +
25mg
98%
in stock  
$116.00   $82.00
- +
100mg
95%
in stock  
$239.00   $167.00
- +
250mg
95%
in stock  
$347.00   $243.00
- +
1g
95%
in stock  
$1,091.00   $764.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA000IVZ
Chemical Name:
Dabrafenib
CAS Number:
1195765-45-7
Molecular Formula:
C23H20F3N5O2S2
Molecular Weight:
519.5624
MDL Number:
MFCD17215684
SMILES:
Nc1nccc(n1)c1sc(nc1c1cccc(c1F)NS(=O)(=O)c1c(F)cccc1F)C(C)(C)C
Properties
Computed Properties
 
Complexity:
817  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
35  
Hydrogen Bond Acceptor Count:
11  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0  
Rotatable Bond Count:
6  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  
XLogP3:
4.8  

Literature

Title: Antiseptic effects of dabrafenib on TGFBIp-induced septic responses.

Journal: Chemico-biological interactions 20171225

Title: Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption.

Journal: Chemico-biological interactions 20160825

Title: Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.

Journal: British journal of cancer 20160315

Title: Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells.

Journal: Scientific reports 20160101

Title: Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.

Journal: Expert opinion on drug metabolism & toxicology 20130701

Title: BRAF inhibitor activity in V600R metastatic melanoma.

Journal: European journal of cancer (Oxford, England : 1990) 20130301

Title: BRAF inhibition and beyond in advanced melanoma.

Journal: Lancet (London, England) 20120728

Title: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Journal: Lancet (London, England) 20120728

Title: Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.

Journal: Archives of dermatology 20120301

Title: Small molecule inhibitors of BRAF in clinical trials.

Journal: Bioorganic & medicinal chemistry letters 20120115

Title: Overcoming metastatic melanoma with BRAF inhibitors.

Journal: Archives of pharmacal research 20110501

Title: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Journal: Nature 20100930

Title: Greger JG, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther, 2012, 11(4), 909-920.

Title: Lee S, et al. Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption. Chem Biol Interact. 2016 Jul 22.

Title: Jung B, et al. Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses. BMB Rep. 2016 Apr;49(4):214-9.

Title: Alexander M Menzies, et al. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther. 2012; 6: 391–405.

Title: Posobiec LM, et al. Early Vaginal Opening in Juvenile Female Rats Given BRAF-Inhibitor Dabrafenib Is Not Associated with Early Physiologic Sexual Maturation. Birth Defects Res B Dev Reprod Toxicol. 2015 Dec;104(6):244-52.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:1195765-45-7 Molecular Formula|1195765-45-7 MDL|1195765-45-7 SMILES|1195765-45-7 Dabrafenib
Catalog No.: AA000IVZ
1195765-45-7,MFCD17215684
1195765-45-7 | Dabrafenib
Pack Size: 5mg
Purity: ≥98%
in stock
$52.00 $36.00
Pack Size: 10mg
Purity: ≥98%
in stock
$99.00 $69.00
Pack Size: 25mg
Purity: 98%
in stock
$116.00 $82.00
Pack Size: 100mg
Purity: 95%
in stock
$239.00 $167.00
Pack Size: 250mg
Purity: 95%
in stock
$347.00 $243.00
Pack Size: 1g
Purity: 95%
in stock
$1,091.00 $764.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA000IVZ
Chemical Name: Dabrafenib
CAS Number: 1195765-45-7
Molecular Formula: C23H20F3N5O2S2
Molecular Weight: 519.5624
MDL Number: MFCD17215684
SMILES: Nc1nccc(n1)c1sc(nc1c1cccc(c1F)NS(=O)(=O)c1c(F)cccc1F)C(C)(C)C
Properties
Complexity: 817  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 0  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 35  
Hydrogen Bond Acceptor Count: 11  
Hydrogen Bond Donor Count: 2  
Isotope Atom Count: 0  
Rotatable Bond Count: 6  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
XLogP3: 4.8  
Literature fold

Title: Antiseptic effects of dabrafenib on TGFBIp-induced septic responses.

Journal: Chemico-biological interactions20171225

Title: Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption.

Journal: Chemico-biological interactions20160825

Title: Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.

Journal: British journal of cancer20160315

Title: Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells.

Journal: Scientific reports20160101

Title: Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.

Journal: Expert opinion on drug metabolism & toxicology20130701

Title: BRAF inhibitor activity in V600R metastatic melanoma.

Journal: European journal of cancer (Oxford, England : 1990)20130301

Title: BRAF inhibition and beyond in advanced melanoma.

Journal: Lancet (London, England)20120728

Title: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Journal: Lancet (London, England)20120728

Title: Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.

Journal: Archives of dermatology20120301

Title: Small molecule inhibitors of BRAF in clinical trials.

Journal: Bioorganic & medicinal chemistry letters20120115

Title: Overcoming metastatic melanoma with BRAF inhibitors.

Journal: Archives of pharmacal research20110501

Title: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Journal: Nature20100930

Title: Greger JG, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther, 2012, 11(4), 909-920.

Title: Lee S, et al. Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption. Chem Biol Interact. 2016 Jul 22.

Title: Jung B, et al. Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses. BMB Rep. 2016 Apr;49(4):214-9.

Title: Alexander M Menzies, et al. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther. 2012; 6: 391–405.

Title: Posobiec LM, et al. Early Vaginal Opening in Juvenile Female Rats Given BRAF-Inhibitor Dabrafenib Is Not Associated with Early Physiologic Sexual Maturation. Birth Defects Res B Dev Reprod Toxicol. 2015 Dec;104(6):244-52.

Building Blocks More >
1227586-36-8
1227586-36-8
2-Amino-5-bromo-4-(hydroxymethyl)pyridine
AA000J9N | MFCD13178296
7789-17-5
7789-17-5
Cesium iodide
AA000JIH | MFCD00010962
122931-48-0
122931-48-0
2-Pyridinesulfonamide, N-[[(4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]-3-(ethylsulfonyl)-
AA000JPS | MFCD01632305
123194-00-3
123194-00-3
4-Amino-1-methylpiperidine-4-carbonitrile
AA000K2Q | MFCD09739421
123387-50-8
123387-50-8
1-Boc-4-methylpiperidine
AA000KE3 | MFCD04114947
123533-41-5
123533-41-5
2-Phenylimidazo[1,2-a]pyridine-3-carboxylic acid
AA000KO3 | MFCD00269226
123792-44-9
123792-44-9
Pyridine, 5-bromo-2-[(1,1-dimethylethyl)sulfonyl]-
AA000L07 | MFCD22196691
124-17-4
124-17-4
Ethanol, 2-(2-butoxyethoxy)-, 1-acetate
AA000LAR | MFCD00009458
1242336-71-5
1242336-71-5
2-(2,4-Dichlorophenyl)oxazole
AA000LNF | MFCD16660292
124499-37-2
124499-37-2
1,4-Dioxaspiro[4.5]decane-8-acetonitrile
AA000M12 | MFCD09037894
Submit
© 2017 AA BLOCKS, INC. All rights reserved.